Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Højflow-nasalcannuliltilførsel af ilt versus konventionel ilttilførsel ved højdesyge med lungeødem

14. november 2026 opdateret af: Ye Fan, Third Military Medical University

Højstrømningsnasalkanyleiltbehandling versus konventionel iltbehandling hos patienter med højdesyge-lunødem: En prospektiv randomiseret kontrolleret undersøgelse

This study aims to evaluate whether High-flow Nasal Cannula Oxygen Therapy (HFNC) provides superior respiratory support compared to Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE).

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

Conventional Oxygen Therapy (COT) is the established first-line treatment for High-Altitude Pulmonary Edema (HAPE). Despite the proven efficacy of High-flow Nasal Cannula (HFNC) in treating other forms of acute respiratory failure and pulmonary edema, its clinical role in the context of HAPE remains poorly defined. To address this gap, the investigators conducted a study comparing the efficacy of HFNC versus COT in providing respiratory support and accelerating clinical recovery for patients with HAPE.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

208

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Yiding Li, Dr.
  • Telefonnummer: +86 13101377031
  • E-mail: fygan@163.com

Studiesteder

    • Tibet
      • Xigazê, Tibet, Kina, 857000
        • Rekruttering
        • NO.953 Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged 18 years or older;
  2. Onset of symptoms related to HAPE (including dyspnea at rest, cough, or exercise intolerance) within 7 days of ascending to high altitude (≥2500m);
  3. Diagnosis of HAPE according to the STAR data reporting guidelines, requiring at least two symptoms (dyspnea at rest, cough, weakness/decreased exercise performance, or chest tightness/congestion) and two clinical signs (rales or wheezing in at least one lung field, central cyanosis, tachypnea, or tachycardia);
  4. Radiographic evidence of pulmonary edema on chest X-ray or CT;
  5. Refusal or inability to undergo immediate descent at the time of presentation;
  6. Capability and willingness to provide written informed consent.

Exclusion criteria:

  1. Known or clinically confirmed pregnancy;
  2. Requirement for emergency intubation (as assessed by the treating clinician) due to cardiac/respiratory arrest, hemodynamic instability, airway compromise, severe hypoxia, or impaired consciousness, etc;
  3. Pulmonary edema or hypoxemia resulting from other medical conditions (e.g., cardiogenic pulmonary edema, sepsis, chronic obstructive pulmonary disease (COPD), pneumothorax, massive pleural effusion, chest trauma, etc.);
  4. Glasgow Coma Scale (GCS) score ≤ 12;
  5. PaCO₂ > 55 mmHg;
  6. Presence of high-altitude cerebral edema;
  7. Receipt of any respiratory support therapy (other than conventional oxygen therapy) prior to admission;
  8. Presence of any contraindication to conventional or nasal oxygen therapy;
  9. Presence of severe medical conditions or abnormal clinical laboratory findings that, in the investigator's judgment, may pose a risk to the patient's safety or interfere with the study's execution and participant completion;
  10. Current participation in other clinical trials;
  11. Refusal to sign the informed consent form.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention Group

High-flow Nasal Cannula Oxygen Therapy (HFNC) plus standard medical management

High-flow Nasal Cannula (HFNC) therapy was administered using a dedicated system with integrated active humidification and a heated-wire circuit, delivered via a wide-bore nasal cannula.

Ingen indgriben: Control Group

Conventional Oxygen Therapy (COT) plus standard medical management

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of treatment failure
Tidsramme: From date of randomization until the time of first documented treatment failure from any cause, assessed up to about 7 days.

Treatment failure: defined as the inability to achieve or maintain the target SpO2 despite optimized oxygen therapy, patient intolerance to the assigned oxygen therapy, or the need for treatment escalation (e.g., non-invasive ventilation or endotracheal intubation) and emergency descent to prevent further clinical deterioration.

From date of randomization until the time of first documented treatment failure from any cause, assessed up to about 7 days.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to weaning off supplemental oxygen
Tidsramme: From date of randomization to oxygen therapy completion (oxygen weaning), an average of 3-5 days.

Hours from randomization to successful weaning to room air.

From date of randomization to oxygen therapy completion (oxygen weaning), an average of 3-5 days.
The Net change in Lung CT Severity Score
Tidsramme: Day 3

Change in Lung CT Severity Score from baseline to Day 3 post-randomization

Day 3
Evolvement of SpO2
Tidsramme: From enrollment to treatment completion, an average of 3-5 days.

SpO₂ is the percentage of oxygen-saturated hemoglobin in the blood, indicating how well oxygen is being delivered throughout the body. It was measured non-invasively using a pulse oximeter, a small device placed on a participant's fingertip, which uses light to estimate blood oxygen levels.

From enrollment to treatment completion, an average of 3-5 days.
Incidence of oxygen therapy-related complications
Tidsramme: From randomization to discharge, assessed up to about 7 days.

Incidence of oxygen therapy-related complications during hospital stay.

From randomization to discharge, assessed up to about 7 days.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Ye Fan, Dr., Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, 83 Xinqiao Zhengjie, Shapingba District, ChongQing 400000, China

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. april 2026

Primær færdiggørelse (Anslået)

22. april 2029

Studieafslutning (Anslået)

22. april 2029

Datoer for studieregistrering

Først indsendt

3. april 2026

Først indsendt, der opfyldte QC-kriterier

11. april 2026

Først opslået (Faktiske)

17. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • HOPE

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner